WO1996002209A1 - Tissue injectable composition and method of use - Google Patents
Tissue injectable composition and method of use Download PDFInfo
- Publication number
- WO1996002209A1 WO1996002209A1 PCT/US1995/007454 US9507454W WO9602209A1 WO 1996002209 A1 WO1996002209 A1 WO 1996002209A1 US 9507454 W US9507454 W US 9507454W WO 9602209 A1 WO9602209 A1 WO 9602209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- particles
- carbon
- substrate particles
- carrier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0059—Cosmetic or alloplastic implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0004—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse
- A61F2/0031—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse for constricting the lumen; Support slings for the urethra
- A61F2/0036—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse for constricting the lumen; Support slings for the urethra implantable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/042—Urinary bladders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/303—Carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00574—Coating or prosthesis-covering structure made of carbon, e.g. of pyrocarbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- This invention relates to an injectable composition of physiologically compatible and
- composition is formulated to be delivered into the body to a tissue site through a small-bore instrument to strengthen, bulk-up and otherwise augment the tissue site and surrounding area.
- Urinary incontinence and vesicourethral reflux are urological disorders that have
- U.S. Patent No's. 5,007,940; 5,158,573; and 5,116,387 to Berg disclose biocompatible compositions comprising discrete, polymeric and silicone rubber bodies injectable into urethral tissue for the purpose of treatment of urinary incontinence by tissue bulking. The most serious adverse effect that may occur
- nonmigration is the administration of properly sized particles. If the particle is too small, it is likely to enter the microvasculature system and travel until it reaches a site of greater constriction.
- Target organs for reposition include the lungs, liver, spleen, brain, kidney, and
- biocompatible, nonmigratory particles that are effectively delivered to the desired tissue site in a lubricative, biocompatible fluid or gel carrier.
- the preferred carrier shall not cause any deleterious effects at or near the site of particle delivery and will be removed from the site by
- composition comprised of a plurality of discrete, physiologically compatible, carbon-coated particles of a pr-* etermir ⁇ ed size range and a lubricative fluid or gel in which the particles are
- the carrier is preferably a biologically compatible solution or suspension.
- particles range in size from 100 microns to 1,000 microns in transverse, cross-sectional dimension.
- composition is designed to be delivered into the body through a small-bore needle
- cannula or catheter and to a tissue site for the purpose of augmenting the tissue site and
- su ⁇ ounding area thereby correcting a defect, filling a void or strengthening the support structures of the tissue.
- the invention is comprised of two components.
- the first is a plurality of carbon-coated particles ranging in size as microbeads or
- microparticles from a minimum of 100 microns to a maximum of 1 ,000 microns.
- the particles are subjected to a coating process in which carbon is deposited as a thin coating or film on an appropriate, paniculate substrate, thereby creating a particle that has a highly
- Zirconium oxide has been found to be especially suitable as such a substrate.
- other metallic substrates including but not limited to
- the second component acts as the lubricative carrier for the carbon-coated particles
- biologically compatible carriers include but are not limited to beta-glucan, hyaluronic acid and derivatives thereof, polyvinyl pyrrolidone or a
- hydrogel derivative thereof dextrans or a hydrogel derivative thereof, glycerol, polyethylene glycol, succinaylated collagen, liquid collagen, and other polysaccharides or biocompatible polymers either singly or in combinations with one or more of the above-referenced solutions.
- the preferred carrier must be capable of being formulated into a viscous fluid or into a self-
- the carrier shall be of sufficient viscosity to provide sufficient viscosity to
- the invention consists of an injectable composition that is a combination of a plurality
- a lubricative fluid or gel that is preferably comprised of a biologically compatible, lubricous solution, suspension, other fluid or gel.
- the particles comprise microbeads or microparticles of a hard, material serving as a
- the substrate material is preferably radiopaque. Different types of carbon coating processes may be utilized, with the particulate substrate being a metallic substance
- LTI Low temperature isotropic pyrolytic carbon
- Pyrolytic derives from the term pyrolysis, which is a thermal decomposition of hydrocarbons to produce a carbon material. Pyrolytic carbon is produced in a process in which
- hydrocarbons and alloying gases are decomposed in a fluidized or floating bed.
- the hydrocarbon pyrolysis results in high carbon, low hydrogen content spheres, which deposit as solids upon the substrate in the
- the spheres may coalesce
- the prefened particulate material is the prefened particulate material.
- Zirconium oxide has been found to be especially suitable as
- Ultra-low-temperature isotropic carbon may be applied as a coating in vacuum vapor
- Carbon can be deposited effectively utilizing ion beams generated from the disassociation of CO 2 , reactive disassociation in vacuum of a hydrocarbon as a result of a
- Vitreous or glass carbons may also serve as the coating material. These are also possible.
- isotropic, monolithic carbons which are formed by pyrolysis of carbonaceous preforms, during which gaseous pyrolysis products diffuse through the shape and are liberated.
- pyrolitic LTI carbon or vitreous carbon is similar to graphite, the common form of carbon, but the alignment between hexagonal planes of atoms
- Pyrolitic caibon is characterized by a more chaotic atomic structure
- the coating process is applied to small substrate particles to produce final, rounded particles that have a smooth carbon-coated surface in the form of a thin, black film.
- pyrolytic carbon renders it particularly suitable for the anticipated body tissue applications. After the carbon coating has been applied, the particles are subjected to a cleaning and sieving
- the particles may range in size from 100 microns to 1,000 microns in average, transverse cross-sectional dimension, and a preferred size range is between 200 and
- the substrate particles are initially milled, extruded or otherwise formed to the desired particle size, in a substantially rounded shape prior to being
- the particles are randomly shaped and rounded, ranging
- the sieving process is such that the minimum particle dimension will pass through a U.S. No. 18 Screen Mesh (1000 micron grid size opening) but will not pass through a U.S. No. 140 Screen Mesh (106 micron grid size). That minimum dimension will be the transverse, cross-sectional dimension on oblong or elongated particles,
- the carrier is preferably an aqueous suspension or solution, other fluid or gel of
- polymeric chains of B-D-glucose commonly referred to as B-glucan.
- the glucose units are linked to each other at the 1-3, 1-4, or 1-6 positions and form polymeric chains ranging to
- B-glucan is a naturally occurring constituent of cell walls in essentially all living
- B-glucan when administered in experimental studies, elicits and augments host defense mechanisms including the steps required to promote healing by first intent, thereby stimulating the reparative processes in the host system. B-glucan is rapidly removed from tissue sites through macrophagic phagocytosis or by enzymatic destruction by serous
- Aqueous solutions, suspensions, fluids, or gels of B-glucan can be produced that have
- the viscosity can be any suitable viscosity.
- the B-glucan has excellent lubricity, thereby creating a particle-carrier composition which is easily
- the carrier will be of sufficient viscosity to assure that the carbon-coated particles
- Suitable carriers include hyaluronic acid, polyvinyl pyrrolidone or a hydrogel derivative thereof, dextran or a hydrogel derivative
- glycerol polyethylene glycol
- succinylated collagen liquid collagen
- emulsions such as corn oil or safflower, or other polysaccharides or biocompatible organic polymers either singly or in combination with one or more of the above-referenced solutions.
- the above-described composition will be injected in a fluid state, e.g., as a slurry, fluid suspension or emulsion, or as a gel through a syringe needle or cannula into a fluid state, e.g., as a slurry, fluid suspension or emulsion, or as a gel through a syringe needle or cannula into a fluid state, e.g., as a slurry, fluid suspension or emulsion, or as a gel through a syringe needle or cannula into a
- the preferred B-glucan carrier When deposited into a soft tissue site, the preferred B-glucan carrier will disperse or be destroyed as set forth above.
- the particles are of an optimum size which will
- the composition may be injected into the tissue of the urinary tract, wherein the selected site may be, for example, the bladder neck, the urethra or urethral
- a syringe was utilized to contain and inject a fluid composition comprised of:
- pyrolytic isotropic LTI carbon-coated zirconium oxide particles in a size range from 200 to 500 microns of a total mass of 400 mg suspended in;
- B-glucan formulated as a 1 % weight by weight aqueous suspension, as the
- test composition was administered by periurethral injection into dogs. Injections were performed such that the bulk of the bladder neck/periurethral tissue was increased but such that the urethral lumen diameter was not compromised. One or more injections of the
- test material were administered in total volumes ranging from 1.9 to 2.5 milliliters.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT95923819T ATE246475T1 (en) | 1994-07-14 | 1995-06-13 | COMPOSITIONS INJECTABLE INTO BODY TISSUE |
EP95923819A EP0771179B1 (en) | 1994-07-14 | 1995-06-13 | Tissue injectable composition |
DE69531450T DE69531450T2 (en) | 1994-07-14 | 1995-06-13 | COMPOSITIONS INJECTABLE IN BODY TISSUE |
CA002194909A CA2194909C (en) | 1994-07-14 | 1995-06-13 | Tissue injectable composition and method of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/274,777 | 1994-07-14 | ||
US08/274,777 US5451406A (en) | 1994-07-14 | 1994-07-14 | Tissue injectable composition and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996002209A1 true WO1996002209A1 (en) | 1996-02-01 |
Family
ID=23049577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/007454 WO1996002209A1 (en) | 1994-07-14 | 1995-06-13 | Tissue injectable composition and method of use |
Country Status (6)
Country | Link |
---|---|
US (1) | US5451406A (en) |
EP (1) | EP0771179B1 (en) |
AT (1) | ATE246475T1 (en) |
CA (1) | CA2194909C (en) |
DE (1) | DE69531450T2 (en) |
WO (1) | WO1996002209A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097218A2 (en) * | 2004-04-08 | 2005-10-20 | Q-Med Ab | Particles for soft tissue augmentation |
US8124120B2 (en) | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
US8877246B2 (en) | 2008-02-29 | 2014-11-04 | Coloplast A/S | Compositions and methods for augmentation and regeneration of living tissue in a subject |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537574B1 (en) | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
US7060287B1 (en) * | 1992-02-11 | 2006-06-13 | Bioform Inc. | Tissue augmentation material and method |
US7968110B2 (en) * | 1992-02-11 | 2011-06-28 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
US5840290A (en) * | 1996-05-30 | 1998-11-24 | University Of Florida Research Foundation | Injectable bio-active glass in a dextran suspension |
US6051247A (en) * | 1996-05-30 | 2000-04-18 | University Of Florida Research Foundation, Inc. | Moldable bioactive compositions |
US5792478A (en) * | 1996-07-08 | 1998-08-11 | Advanced Uro Science | Tissue injectable composition and method of use |
CA2263421C (en) * | 1996-08-23 | 2012-04-17 | William A. Cook | Graft prosthesis, materials and methods |
US6666892B2 (en) * | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
US8716227B2 (en) * | 1996-08-23 | 2014-05-06 | Cook Biotech Incorporated | Graft prosthesis, materials and methods |
US6645138B2 (en) | 1997-09-12 | 2003-11-11 | Uromedica, Inc. | Adjustable implantable genitourinary device |
US7364540B1 (en) * | 1997-06-12 | 2008-04-29 | Uromedica, Inc. | Implantable device and method for adjustably restricting a body lumen |
US6419624B1 (en) * | 1999-10-11 | 2002-07-16 | Uromedica, Inc. | Apparatus and method for inserting an adjustable implantable genitourinary device |
US6579224B1 (en) | 1999-10-11 | 2003-06-17 | Uromedica, Inc. | Apparatus and method for inserting an adjustable implantable genitourinary device |
US6045498A (en) | 1997-06-12 | 2000-04-04 | Uromedica, Inc. | Method for adjustably restricting a body lumen |
FR2764514B1 (en) * | 1997-06-13 | 1999-09-03 | Biopharmex Holding Sa | IMPLANT INJECTED IN SUBCUTANEOUS OR INTRADERMAL WITH CONTROLLED BIORESORBABILITY FOR REPAIR OR PLASTIC SURGERY AND AESTHETIC DERMATOLOGY |
EP1009333A1 (en) * | 1997-07-10 | 2000-06-21 | US Biomaterials Corporation | Moldable bioactive compositions |
US7637948B2 (en) | 1997-10-10 | 2009-12-29 | Senorx, Inc. | Tissue marking implant |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US6309420B1 (en) | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
US20030135206A1 (en) | 1998-02-27 | 2003-07-17 | Curon Medical, Inc. | Method for treating a sphincter |
US6660301B1 (en) * | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
CA2322954C (en) | 1998-03-06 | 2011-06-07 | Biosepra Inc. | Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
AU3203599A (en) | 1998-04-01 | 1999-10-18 | Parallax Medical, Inc. | Pressure applicator for hard tissue implant placement |
US6161034A (en) * | 1999-02-02 | 2000-12-12 | Senorx, Inc. | Methods and chemical preparations for time-limited marking of biopsy sites |
US8882850B2 (en) * | 1998-12-01 | 2014-11-11 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
US6251064B1 (en) * | 1998-12-11 | 2001-06-26 | Enteric Medical Technologies, Inc. | Method for creating valve-like mechanism in natural body passageway |
US6595910B2 (en) | 1998-12-11 | 2003-07-22 | Scimed Life Systems, Inc. | Method for treating fecal incontinence |
US7132582B2 (en) * | 2003-05-30 | 2006-11-07 | Council Of Scientific And Industrial Research | Catalytic process for the preparation of isolongifolene |
US6238335B1 (en) * | 1998-12-11 | 2001-05-29 | Enteric Medical Technologies, Inc. | Method for treating gastroesophageal reflux disease and apparatus for use therewith |
US6371904B1 (en) | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6356782B1 (en) | 1998-12-24 | 2002-03-12 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US6862470B2 (en) | 1999-02-02 | 2005-03-01 | Senorx, Inc. | Cavity-filling biopsy site markers |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US20090030309A1 (en) | 2007-07-26 | 2009-01-29 | Senorx, Inc. | Deployment of polysaccharide markers |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
US7651505B2 (en) | 2002-06-17 | 2010-01-26 | Senorx, Inc. | Plugged tip delivery for marker placement |
EP1165178A1 (en) * | 1999-03-01 | 2002-01-02 | Advanced Biomedical Devices, Inc. | Implant positioning system and method |
WO2000056254A1 (en) | 1999-03-24 | 2000-09-28 | Parallax Medical, Inc. | Non-compliant system for delivery of implant material |
ATE427074T1 (en) | 1999-04-30 | 2009-04-15 | Uromedica Inc | DEVICE HAVING AN ADJUSTABLE SLING FOR TREATING STRESS-RELATED URINARY INCONTINENCE |
US20040229295A1 (en) * | 1999-05-17 | 2004-11-18 | Marchitto Kevin S. | Activated delivery of biomolecules using electromagnetic energy |
US6575991B1 (en) | 1999-06-17 | 2003-06-10 | Inrad, Inc. | Apparatus for the percutaneous marking of a lesion |
US6835200B2 (en) | 1999-06-22 | 2004-12-28 | Ndo Surgical. Inc. | Method and devices for tissue reconfiguration |
US6821285B2 (en) | 1999-06-22 | 2004-11-23 | Ndo Surgical, Inc. | Tissue reconfiguration |
US6663639B1 (en) | 1999-06-22 | 2003-12-16 | Ndo Surgical, Inc. | Methods and devices for tissue reconfiguration |
US8287554B2 (en) | 1999-06-22 | 2012-10-16 | Ethicon Endo-Surgery, Inc. | Method and devices for tissue reconfiguration |
US6494888B1 (en) | 1999-06-22 | 2002-12-17 | Ndo Surgical, Inc. | Tissue reconfiguration |
US7846180B2 (en) | 1999-06-22 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Tissue fixation devices and methods of fixing tissue |
US6358197B1 (en) | 1999-08-13 | 2002-03-19 | Enteric Medical Technologies, Inc. | Apparatus for forming implants in gastrointestinal tract and kit for use therewith |
KR20020043557A (en) * | 1999-08-13 | 2002-06-10 | 바이오폼 인크. | Tissue Augmentation Material and Methods |
US6277392B1 (en) * | 1999-09-16 | 2001-08-21 | Carbon Medical Technologies, Inc. | Tissue injectable composition |
US6502574B2 (en) | 1999-09-17 | 2003-01-07 | Pi Medical, Inc. | Lateral stiffening snoring treatment |
US6431174B1 (en) | 2000-08-10 | 2002-08-13 | Pi Medical, Inc. | Method and apparatus to treat conditions of the naso-pharyngeal area |
US6783515B1 (en) | 1999-09-30 | 2004-08-31 | Arthrocare Corporation | High pressure delivery system |
EP1114618A3 (en) | 2000-01-04 | 2001-08-22 | Ethicon Endo-Surgery, Inc. | Surgical instrument for applying beads to tissue |
WO2001070289A2 (en) | 2000-03-20 | 2001-09-27 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
US6436424B1 (en) * | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
US7338657B2 (en) * | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
DE01918975T1 (en) | 2000-03-24 | 2006-04-13 | Biosphere Medical, Inc., Rockland | Microspheres for active embolization |
US6540789B1 (en) | 2000-06-15 | 2003-04-01 | Scimed Life Systems, Inc. | Method for treating morbid obesity |
US6355275B1 (en) | 2000-06-23 | 2002-03-12 | Carbon Medical Technologies, Inc. | Embolization using carbon coated microparticles |
WO2002011696A2 (en) * | 2000-08-08 | 2002-02-14 | Ev & M | Active tissue augmentation materials and method |
US6394965B1 (en) | 2000-08-15 | 2002-05-28 | Carbon Medical Technologies, Inc. | Tissue marking using biocompatible microparticles |
US6425854B1 (en) * | 2000-10-02 | 2002-07-30 | Genyx Medical, Inc. | Method for delivering non-biodegradable bulking composition to a urological site |
US6726898B2 (en) | 2000-11-17 | 2004-04-27 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
US6576226B1 (en) | 2000-11-17 | 2003-06-10 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
AU2002239290A1 (en) | 2000-11-20 | 2002-06-03 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US9080146B2 (en) | 2001-01-11 | 2015-07-14 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
US20070191964A1 (en) * | 2001-04-04 | 2007-08-16 | Arthrocare Corporation | Enhanced visibility materials for implantation in hard tissue |
WO2002100444A1 (en) * | 2001-06-08 | 2002-12-19 | Biosphere Medical Inc. | Colloidal metal labelled microparticles, their production and use |
US20030161824A1 (en) * | 2002-02-27 | 2003-08-28 | Rackley Raymond R. | Bulking agent needle apparatus and method of using the needle apparatus |
US20030171451A1 (en) * | 2002-03-11 | 2003-09-11 | White Daniel A. | Bony tissue fillers and restoratives containing biocompatible particle |
US7695427B2 (en) | 2002-04-26 | 2010-04-13 | Torax Medical, Inc. | Methods and apparatus for treating body tissue sphincters and the like |
US20040105890A1 (en) * | 2002-05-28 | 2004-06-03 | Carbon Medical Technologies, Inc. | Biocompatible injectable materials |
US7175589B2 (en) * | 2002-07-02 | 2007-02-13 | The Foundry Inc. | Methods and devices for luminal and sphincter augmentation |
US20040194266A1 (en) * | 2002-08-19 | 2004-10-07 | Carter Linda A. | Burn, sunburn, and cellulite treatment system |
US20060036158A1 (en) | 2003-11-17 | 2006-02-16 | Inrad, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
WO2004047651A2 (en) * | 2002-11-25 | 2004-06-10 | Boston Scientific Limited | Injection device for treating mammalian body |
US7992566B2 (en) | 2002-12-30 | 2011-08-09 | Quiescence Medical, Inc. | Apparatus and methods for treating sleep apnea |
US7381222B2 (en) * | 2002-12-30 | 2008-06-03 | Quiescence Medical, Inc. | Stent for maintaining patency of a body region |
US7647931B2 (en) | 2002-12-30 | 2010-01-19 | Quiescence Medical, Inc. | Stent for maintaining patency of a body region |
US20050119562A1 (en) * | 2003-05-23 | 2005-06-02 | Senorx, Inc. | Fibrous marker formed of synthetic polymer strands |
US7877133B2 (en) * | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
US20050033157A1 (en) * | 2003-07-25 | 2005-02-10 | Klein Dean A. | Multi-modality marking material and method |
US20060246137A1 (en) * | 2003-07-30 | 2006-11-02 | Laurence Hermitte | Complex matrix for biomedical use |
JP2005161028A (en) * | 2003-10-20 | 2005-06-23 | Greatbatch-Hittman Inc | Implantable electrical lead wire |
US20050273002A1 (en) | 2004-06-04 | 2005-12-08 | Goosen Ryan L | Multi-mode imaging marker |
US20100261951A1 (en) * | 2004-02-23 | 2010-10-14 | Uromedica, Inc. | Method and apparatus for an adjustable implantable continence device |
US20060241339A1 (en) * | 2005-02-23 | 2006-10-26 | Cook Timothy C | Method and apparatus for an adjustable implantable continence device |
WO2005118060A2 (en) * | 2004-04-30 | 2005-12-15 | Boston Scientific Limited | Apparatus with partially insulated needle for measuring tissue impedance and method using same |
JP4885866B2 (en) | 2004-10-25 | 2012-02-29 | セロノヴァ バイオサイエンスィズ ジャーマニー ゲーエムベーハー | Fillable polyphosphazene-containing particles for therapeutic and / or diagnostic applications and methods for their preparation and use |
US20210299056A9 (en) | 2004-10-25 | 2021-09-30 | Varian Medical Systems, Inc. | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
US9107850B2 (en) | 2004-10-25 | 2015-08-18 | Celonova Biosciences, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US9114162B2 (en) | 2004-10-25 | 2015-08-25 | Celonova Biosciences, Inc. | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
US8663225B2 (en) * | 2004-11-12 | 2014-03-04 | Medtronic, Inc. | Hydrogel bone void filler |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
US20060257445A1 (en) * | 2005-04-29 | 2006-11-16 | Medtronic, Inc. | Devices for augmentation of lumen walls |
US20060257444A1 (en) * | 2005-04-29 | 2006-11-16 | Medtronic, Inc. | Devices for augmentation of lumen walls |
US7984717B2 (en) * | 2005-04-29 | 2011-07-26 | Medtronic, Inc. | Devices for augmentation of lumen walls |
CN104815331A (en) | 2005-05-09 | 2015-08-05 | 生物领域医疗公司 | Compositions and methods using microspheres and non-ionic contrast agents |
CA2562580C (en) | 2005-10-07 | 2014-04-29 | Inrad, Inc. | Drug-eluting tissue marker |
US20070184087A1 (en) * | 2006-02-06 | 2007-08-09 | Bioform Medical, Inc. | Polysaccharide compositions for use in tissue augmentation |
FR2897775B1 (en) * | 2006-02-24 | 2013-05-03 | Elisabeth Laugier | BIOMATERIAU, INJECTABLE IMPLANT COMPRISING IT, PROCESS FOR PREPARING THE SAME AND USES THEREOF |
US8147397B1 (en) | 2006-05-19 | 2012-04-03 | Carbon Medical Technologies, Inc. | Urethral needle guide device |
EP2037850A2 (en) | 2006-07-06 | 2009-03-25 | Quiescence Medical Inc | Apparatus and methods for treating sleep apnea |
US8064987B2 (en) | 2006-10-23 | 2011-11-22 | C. R. Bard, Inc. | Breast marker |
US20080107744A1 (en) * | 2006-11-06 | 2008-05-08 | Jack Fa-De Chu | Injectable hollow tissue filler |
US9579077B2 (en) | 2006-12-12 | 2017-02-28 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
US8401622B2 (en) | 2006-12-18 | 2013-03-19 | C. R. Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
US7776840B2 (en) | 2007-02-21 | 2010-08-17 | Cutanea Life Sciences, Inc. | Methods of use of biomaterial and injectable implant containing biomaterial |
US8852216B2 (en) | 2007-03-23 | 2014-10-07 | Ethicon Endo-Surgery, Inc. | Tissue approximation methods |
WO2008157059A1 (en) * | 2007-06-15 | 2008-12-24 | Ethicon, Inc. | Tissue fragment compositions for the treatment of incontinence |
US20090177192A1 (en) * | 2007-07-13 | 2009-07-09 | Scimed Life Systems, Inc. | Method for ablating tissue to facilitate implantation and apparatus and kit for use therewith |
US8262626B2 (en) * | 2007-10-23 | 2012-09-11 | Boston Scientific Scimed, Inc. | Apparatus and method for treating tissue |
WO2009079555A2 (en) * | 2007-12-17 | 2009-06-25 | Anna Love | Soft tissue filler |
WO2009099767A2 (en) | 2008-01-31 | 2009-08-13 | C.R. Bard, Inc. | Biopsy tissue marker |
US20100016808A1 (en) * | 2008-07-17 | 2010-01-21 | Bioform Medical, Inc. | Thin-Walled Delivery System |
US9327061B2 (en) | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
BRPI0823399B8 (en) | 2008-12-30 | 2021-06-22 | Bard Inc C R | marker release device for tissue marker positioning |
US20100204570A1 (en) * | 2009-02-06 | 2010-08-12 | Paul Lubock | Anchor markers |
US20110098731A1 (en) * | 2009-10-26 | 2011-04-28 | Eric Whitbrook | Magnetically assisted clasps for prosthetic implants, and related methods |
EP2498763A4 (en) | 2009-11-09 | 2015-10-07 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
AU2010314994B2 (en) | 2009-11-09 | 2016-10-06 | Spotlight Technology Partners Llc | Fragmented hydrogels |
US9265649B2 (en) | 2010-12-13 | 2016-02-23 | Quiescence Medical, Inc. | Apparatus and methods for treating sleep apnea |
USD715442S1 (en) | 2013-09-24 | 2014-10-14 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716450S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716451S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715942S1 (en) | 2013-09-24 | 2014-10-21 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
US11918728B2 (en) * | 2014-04-17 | 2024-03-05 | ImMutriX Therapeutics, Inc. | Therapeutic compositions for viral-associated disease states and methods of making and using same |
US9669151B2 (en) * | 2014-04-17 | 2017-06-06 | ImMutriX Therapeutics, Inc. | Therapeutic compositions for viral-associated disease states and methods of making and using same |
US11510766B2 (en) | 2019-02-14 | 2022-11-29 | Uromedica, Inc. | Method and apparatus for monitoring implantable device for urinary continence |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3977896A (en) * | 1972-03-09 | 1976-08-31 | General Atomic Company | Process for depositing pyrolytic carbon coatings |
US5158573A (en) * | 1989-06-09 | 1992-10-27 | American Medical Systems, Inc. | Injectable polymeric bodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3783868A (en) * | 1971-05-06 | 1974-01-08 | Gulf Oil Corp | Percutaneous implant |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US4773393A (en) * | 1986-07-03 | 1988-09-27 | C. R. Bard, Inc. | Hypodermically implantable genitourinary prosthesis |
US5258028A (en) * | 1988-12-12 | 1993-11-02 | Ersek Robert A | Textured micro implants |
US5116387A (en) * | 1989-06-09 | 1992-05-26 | American Medical Systems, Inc. | Preparation of injectable polymeric bodies |
US5007940A (en) * | 1989-06-09 | 1991-04-16 | American Medical Systems, Inc. | Injectable polymeric bodies |
FR2654345A1 (en) * | 1989-09-05 | 1991-05-17 | Hamann Sylvie | Biocompatible covering consisting of a carbon powder |
US5204382A (en) * | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
-
1994
- 1994-07-14 US US08/274,777 patent/US5451406A/en not_active Expired - Lifetime
-
1995
- 1995-06-13 DE DE69531450T patent/DE69531450T2/en not_active Expired - Fee Related
- 1995-06-13 WO PCT/US1995/007454 patent/WO1996002209A1/en active IP Right Grant
- 1995-06-13 AT AT95923819T patent/ATE246475T1/en not_active IP Right Cessation
- 1995-06-13 CA CA002194909A patent/CA2194909C/en not_active Expired - Fee Related
- 1995-06-13 EP EP95923819A patent/EP0771179B1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3977896A (en) * | 1972-03-09 | 1976-08-31 | General Atomic Company | Process for depositing pyrolytic carbon coatings |
US5158573A (en) * | 1989-06-09 | 1992-10-27 | American Medical Systems, Inc. | Injectable polymeric bodies |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124120B2 (en) | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
WO2005097218A2 (en) * | 2004-04-08 | 2005-10-20 | Q-Med Ab | Particles for soft tissue augmentation |
WO2005097218A3 (en) * | 2004-04-08 | 2005-12-01 | Q Med Ab | Particles for soft tissue augmentation |
EP1734894B1 (en) | 2004-04-08 | 2016-08-03 | Q-Med AB | Particles for soft tissue augmentation |
US11458226B2 (en) | 2004-04-08 | 2022-10-04 | Galderma Holding SA | Method of soft tissue augmentation |
US8877246B2 (en) | 2008-02-29 | 2014-11-04 | Coloplast A/S | Compositions and methods for augmentation and regeneration of living tissue in a subject |
Also Published As
Publication number | Publication date |
---|---|
CA2194909A1 (en) | 1996-02-01 |
EP0771179A1 (en) | 1997-05-07 |
DE69531450T2 (en) | 2004-05-06 |
US5451406A (en) | 1995-09-19 |
EP0771179A4 (en) | 1998-07-08 |
EP0771179B1 (en) | 2003-08-06 |
CA2194909C (en) | 1999-07-13 |
ATE246475T1 (en) | 2003-08-15 |
DE69531450D1 (en) | 2003-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5451406A (en) | Tissue injectable composition and method of use | |
US5792478A (en) | Tissue injectable composition and method of use | |
US6277392B1 (en) | Tissue injectable composition | |
JP2995090B2 (en) | Compositions and methods for tissue augmentation | |
US20040028676A1 (en) | Swallowing system tissue modifier | |
US7491243B2 (en) | Method of modifying a lower esophagus | |
AU674308B2 (en) | Use of injectable biomaterials for the repair and augmentation of the anal sphincters | |
US20080311172A1 (en) | Programmed-release, nanostructured biological construct | |
US20130004560A1 (en) | Polymer Nanofilm Coatings | |
US20080107744A1 (en) | Injectable hollow tissue filler | |
JPH07278203A (en) | Glycosaminoglycan-synthetic polymer combination | |
US20040105890A1 (en) | Biocompatible injectable materials | |
Tsai et al. | Injectable biomaterials for incontinence and vesico‐ureteral reflux: Current status and future promise | |
RI | PLGA microspheres in hyaluronic acid gel as a potential bulking agent for urologic and dermatologic injection therapies | |
Mann-Gow et al. | Novel bioceramic urethral bulking agents elicit improved host tissue responses in a rat model | |
Russinko et al. | Endoscopic correction of reflux | |
WO2003072196A1 (en) | Lower esophagus tissue modifier | |
Curti | Injectable biomaterials | |
JP2001247483A (en) | Infusion for preventing urine incontinence and vesicoureteral reflux |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2194909 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995923819 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995923819 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995923819 Country of ref document: EP |